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Abstract
Objective
To evaluate the area of the vascular ﬂare in familial amyloid polyneuropathy (FAP).
Methods
Healthy controls and patients with genetically conﬁrmed FAP were prospectively examined, on
the upper and lower limbs, for thermal sensitivity (Medoc TSA-II thermal analyzer) and for
axon reﬂex-mediated ﬂare. The latter was induced by iontophoresis of histamine on the forearm
and leg on 2 diﬀerent visits. We used laser Doppler imaging (LDI) to measure the ﬂare area
(LDIﬂare).
Results
Six patients had FAP of variable severity; 1 had generalized analgesia secondary to leprosy (used
as a positive control). The median Neurological Impairment Score–Lower Limbs (NIS-LLs)
was 6 (0–27). The warmth detection thresholds in the feet were higher in patients (median 43°,
interquartile range 39.0°–47.6°) compared with controls (37.4°, 35.3°–39.2°), indicating small
ﬁber impairment. On the leg, LDIﬂare was smaller in the patients on 2 consecutive visits
(controls: median 13.0 and 13.3 cm2, IQR 9.7–22.8 and 8.3–16.9; patients 6.9 and 8.0 cm2,
2.6–10.8 and 6.4–12.1; p = 0.011). LDIﬂare on the leg was correlated with NIS-LL (Spearman
rank correlation 0.73, p = 0.09 on the ﬁrst visit; Spearman rank correlation 0.85, p = 0.03 on the
second visit).
Conclusions
Our study underscores that histamine-induced axon reﬂex–mediated vascular ﬂare on the leg is
reduced in proportion to disease severity in patients with FAP.
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Familial amyloid polyneuropathies (FAPs) are a group of life-
threatening multisystem disorders transmitted as an autoso-
mal dominant trait. Nerve lesions are induced by deposits of
amyloid ﬁbrils most commonly due to a transthyretin (TTR)
gene mutation. The most frequently identiﬁed cause is the
TTR Val30Met mutation.1,2 TTR-FAP typically causes early
length-dependent small ﬁber polyneuropathy with alteration
of temperature and pain sensations including neuropathic
pain. This neurologic deﬁcit typically points to involvement of
unmyelinated and small myelinated ﬁbers.2,3 Diagnosis of
C-ﬁber impairment is challenging; however, the axon reﬂex
can be assessed by objective approaches.4,5 The axon reﬂex is
a physiologic phenomenon caused by the excitation of dermal
C-ﬁbers. Nerve impulses invade peripheral branches anti-
dromically causing vascular dilatation, the so-called axon re-
ﬂex ﬂare reaction.4 For a long time, this ﬂare reaction was
considered unreliable as a clinical tool, making thermotesting
the only recognized biomarker despite its subjectivity.1
However, recent studies using laser Doppler imaging (LDI)
have demonstrated a correlation between the reduced ﬂare
size in small ﬁber neuropathies6 and nerve ﬁber density in skin
biopsies, which is also reduced.5,7
Our aims were to establish (1) whether the surface area of
neurogenic ﬂare triggered by a standard stimulus could be
reliably and reproducibly measured by LDI in healthy controls
and patients with TTR-FAP, (2) whether this method could
discriminate between the 2 groups of participants, and (3)
whether the surface area of the ﬂare in patients was reduced in
proportion to TTR-FAP disease severity.
Methods
Standard protocol approvals, registrations,
and patient consents
This project was approved by the Swiss Ethics Committee on
research involving humans. All participants provided written
informed consent.
Participants
Seven patients and 10 healthy controls were recruited pro-
spectively for this study between spring and fall 2015. All
controls were examined to ascertain their good health status
including absence of skin disorders.
Patients were recruited from our own registry based on 2
inclusion criteria: the presence of neuropathic symptoms
(small ﬁber with or without large ﬁber involvement) and an
amyloid TTR (ATTR) mutation conﬁrmed genetically.
Patients with liver transplantation could be included. All
patients underwent systematic interview and examination by
the same neurologist (T.K.) and had a thorough laboratory
and imaging workup. Clinical symptoms were assessed by the
Neurological Symptom Score (NSS) that includes motor,
sensory, and autonomic items.8 The examination performed
in a temperature-controlled room included testing muscle
strength, tendon reﬂexes, and sensory function testing in-
cluding light touch, pinprick, vibration, joint position sense,
and thermal sensation to calculate the Neurological Impair-
ment Score–Lower Limbs (NIS-LLs).9 ATTR patients were
classiﬁed according to the Clinical Staging of TTR-FAP, the
PolyNeuropathy Disability (PND) score, and the Portuguese
severity classiﬁcation of TTR-FAP.1
Investigation techniques
The included patients underwent standard electrophysiologic
recordings of median, sural, and ﬁbular nerve conduction on
both sides. Nerve conduction studies were considered ab-
normal if either nerve conduction velocity or amplitude of the
sensory nerve action potentials or compound motor action
potentials were abnormal (normal values from our de-
partment were used).
Quantitative sensitivity testing
Thermotesting was performed in a temperature-controlled
room using a warm and cold perception threshold TSA-II
NeuroSensory Analyzer (Medoc Advanced Medical Systems,
Durham, NC). The established method of limits algorithm as
reported from the German Research Network on Neuro-
pathic Pain was also used.10 In short, a thermode of 9 cm2 was
attached to the skin over the dorsum of the hand and foot
bilaterally, and temperature ramps of 1°C/s were applied
starting from 32°C. Participants were asked to press a button
when they felt a cold or warm sensation. The investigator
memorized instructions so that she could present them in
a uniform fashion to each participant.
Laser Doppler imaging
The spatial distribution of skin blood ﬂow (SkBF) was
recorded with a LDI (software version 5.01; Moor Instru-
ments, Axminster, United Kingdom) using a scanning laser
beam at a wavelength of 633 nm, as previously described.11,12
Histamine induced axon reflex
LDI was used to quantitate the ﬂare response induced by the
iontophoresis of histamine (LDIﬂare). This response is neu-
rologically mediated as it is blocked by surface anesthesia, as
Glossary
ATTR = amyloid transthyretin; AUC = area under the curve; FAP = familial amyloid polyneuropathy; LDI = laser Doppler
imaging; NIS-LL = Neurological Impairment Score—Lower Limbs; NSS = Neurological Symptom Score; PND =
polyneuropathy disability; QST = quantitative sensitivity testing; ROC = receiver operating characteristic; SkBF = skin blood
ﬂow; TTR = transthyretin.
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previously shown,13 and veriﬁed by us in preliminary experi-
ments in healthy controls (data not shown).
Methodological details
A 3.5 × 4.5 cm zone of skin devoid of visible superﬁcial veins
was chosen on the volar face of the forearm, or on the lateral
side of the calf, from which a baseline LDI scan was obtained.
A ring-shaped chamber made of rubber, with an internal di-
ameter of 0.8 mm ﬁtted with a copper electrode, was then
ﬁxed to the center of the zone (using double-sided tape) and
ﬁlled to the rim with 1% histamine in deionized water. A
reference ECG electrode was placed similarly, nearby. Both
electrodes were connected to a current source (MIC-1e
iontophoresis controller; Moor Instruments). A direct current
of either 20 or 100 μA was applied for 60 seconds. As hista-
mine in solution is negatively charged, the iontophoresis
chamber was on the positive end of the controller. Once
current delivery was terminated, the chamber was removed,
the skin dried, and the area directly exposed to the histamine
solution was masked with a circular piece of opaque tape. Five
consecutive LDI scans of the zone were then acquired at
a frequency of one every 2 minutes. For each of them, the
spatial extension of SkBF increase (ﬂare area) was de-
termined. The maximal ﬂare area expressed in cm2 was con-
sidered as quantiﬁcation of the axon reﬂex within the probed
skin zone. Each recorded image consisted of approximately
20,000 pixels, each with an attached ﬂux value. Within the
post-iontophoresis scans, any pixel whose value exceeded
a speciﬁc threshold was considered part of the ﬂare area. The
chosen threshold was the 99th percentile of all pixel values in
the baseline image.
Because of its potential confounding eﬀect, surface tempera-
ture within the chosen skin zone was systematically recorded
with a thermocouple in the minute before iontophoresis.
Heat-conducting paste was used to ensure proper thermal
contact between the skin and the thermocouple.
Protocol
Each participant was examined during 3 successive visits
separated by at least 3 days. Visits 1 and 2 were for recording
the histamine ﬂare at various locations, whereas quantitative
sensitivity testing (QST) was performed on visit 3. The same
investigator (the ﬁrst author, I.C.-R.) performed all exami-
nations between 8 and 12 AM, in a quiet temperature-
controlled room (22°C–24°C), with the participant lying
comfortably on a hospital bed.
On visit 1, 4 pairs of skin zones were chosen, 1 on each forearm
and 1 on each calf. Zones within each pair were at least 10 cm
apart and were both allocated to receive histamine iontopho-
resis, with a current intensity of 20 μA on 1 zone and 100 μA on
the other. On the upper and lower limbs, treated zones at both
intensities were placed as symmetrically as possible and their
location recorded on transparent ﬁlm. A total of 8 histamine
ﬂares were thus recorded: 2 intensities on each of the 4 limbs.
The order of rotation between limbs and for intensities on
limbs was randomized. The whole procedure including setup,
acquisition of baseline, iontophoresis, acquisition of post-
iontophoresis images required approximately 30 minutes,
making for a total visit duration of 4 hours.
For each participant, visit 1 protocol was repeated identically
on visit 2, so as to assess the intraindividual variability. In
particular, the recording zones were repositioned as exactly as
possible at the same spot (made possible by the aforemen-
tioned recording on transparent ﬁlm), with intensity alloca-
tion and rotation order identical to those of visit 1.
Data analysis
Histamine ﬂare and local skin temperature data were evaluated
statistically with mixed-model analysis of variance, using the
xtmixed procedure in Stata version 12 (Stata Corp LP).
Responses obtained at the same iontophoretic current intensity
at symmetrical locations were considered as replicates, and data
from the upper and lower limbs were analyzed separately. Thus,
the model comprised participant group (control or patient),
current intensity (20 or 100 μA), visit number (1 or 2), and all
2- and 3-way interactions. In a second step, interactions with
p values > 0.1 were removed. The p values reported in the
results are from this more parsimonious model.
The same general method was used to evaluate each of the 4
outcome measures generated by QST testing (detection and
pain thresholds for warm and cold stimulations). In this case,
the model was simpler because there was only 1 visit and that
stimulus intensity was not a factor.
The relationship between histamine ﬂare and clinical severity
score (NIS-LL) was assessed with Spearman rank correlation
coeﬃcient. Finally, we compared the ability of histamine ﬂare
and QST data to discriminate between groups, using receiver
operating characteristic (ROC) curve analysis. Logistic re-
gression was performed with group membership as the out-
come variable and either histamine ﬂare at a speciﬁc intensity
or speciﬁc QST responses as predictors (procedure logistic,
followed by the lroc command in Stata). The area under the
ROC curve (AUC) was calculated. The AUC can range from
0.5 to 1, with the former value indicating no, and the latter,
perfect discriminating ability.
Results
We recruited 6 patients, all women, with FAP of variable
severity (table 1). All had a conﬁrmed mutation in the TTR
gene: Val30Met in 5 cases and Glu89Lys in one. As a positive
control (table 1), we included a seventh male patient with
generalized analgesia secondary to lepromatous leprosy. His
individual data indicated below is excluded from all statistical
calculations (see Patients’ characteristics). By “patient group”
(or “patients”), we therefore mean only the 6 patients with
FAP. Of the 10 healthy controls, 5 were women and the
remaining were men. Their median age was 50 years (range
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20–64). For comparison, the median age of the 6 FAP
patients was also 50 years (range 37–58).
Patients’ characteristics
All underwent extensive blood workup and imaging studies
and excluded metabolic, immunologic, or infectious causes of
small ﬁber neuropathy, in particular, diabetes, neurodegen-
erative diseases, and paraneoplastic syndromes.
Table 1 contains a detailed description of our patients.
Patients were overweight with a median body mass index of
29.4 kg/m2 (range 28.5–31.9) corresponding to the range of
the controls (mean 29.8 kg/m2: 27.5–31.7). The median
duration of FAP was 12 years. Echocardiography was abnor-
mal in P04 and P06 only. Nerve conduction studies revealed
carpal tunnel syndrome in 4 patients (P01, P02, P04, and
P06) and reduced or absent sural/ﬁbular nerve potentials in 3
(P01, P03, and P04). Four patients had undergone liver
transplantation. Among them, the patient with the GLu89Lys
mutation (P04) also had a heart transplant, as published
previously.14 Clinical manifestations were scored according to
NSS, a well-disseminated score used to quantify symptoms in
patients with neuropathies of various causes, and all had
neuropathic symptoms; neurologic examination was quanti-
ﬁed using scores dedicated to patients with FAP (the so-called
NIS-LL). These scores were correlated with clinical FAP se-
verity and with signs of large nerve ﬁber neuropathy on ex-
amination. As it can be deduced from NSS and NIS-LL data,
patients P02, P05, and P06 were mildly aﬀected having only
a small nerve ﬁber neuropathy. Patients P01, P03, and P04
had the highest NSS and NIS-LL scores and were the most
aﬀected having concomitant small and large nerve ﬁber neu-
ropathy. These 3 patients had abnormal sensory nerve action
potentials. Concerning the clinical staging of the disease, all 6
patients were at stage I of the Clinical Staging of TTR-FAP,
a stage used to start therapeutic options in the clinical setting.
Patients were heterogeneously distributed according to the
PND score (median 1 of 4) or to the Portuguese severity
classiﬁcation of TTR-FAP (median 2 of 6). The patient with
leprosy was the most severely aﬀected.
Thermotesting
Thermotesting results from the hands and feet in the 2 groups
are shown in table 2. Patients diﬀered statistically from con-
trols on the hands and on the feet, with respect to detection
threshold for both warm and cold. Diﬀerences were more
marked on the feet, however, indicating length-dependent
small ﬁber impairment in the patients.
Histamine flare
Figure 1 shows the area of the ﬂare induced by the 2 ionto-
phoretic doses of histamine, measured by LDI on the forearms
and legs on visits 1 and 2, for each study participant. Regarding
statistical analysis, the only interaction terms that came out
marginally signiﬁcant when ﬁtting the full model was between
the group and the iontophoretic dose (p = 0.07, below the
predeﬁned level of 0.1, see Methods). Therefore, the statisticalTa
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results reported here are from a model comprising simple main
eﬀects and this speciﬁc interaction. The dose-response eﬀect
was clearly visible and statistically highly signiﬁcant on both
visits (p < 0.001). On the forearm, the histamine ﬂare area did
not diﬀer, at either dose, between the 2 groups (p = 0.30). By
contrast, on the leg, this response was less intense in patients, at
least for the higher dose of histamine, on both visit 1 (controls:
median 13.0 cm2, interquartile range [IQR] 9.7–22.8; patients:
median 6.9 cm2, IQR 2.6–10.8; p = 0.011 vs controls) and visit
2 (controls: median 13.3 cm2, IQR 8.3–16.9; patients: median
8.0 cm2, IQR 6.4–12.1; p = 0.011).
The measurements of local skin temperature (T_skin) per-
formed before each iontophoresis are detailed in table e-1
(links.lww.com/NXG/A61). On average, T_skin appeared
slightly but signiﬁcantly lower in patients compared with
controls. Statistical analysis was repeated while adding this
possible confounder to the model with essentially identical
results: the dose-response eﬀect remained (p < 0.001); the
diﬀerence in the ﬂare area between patients and controls was
still signiﬁcant on the leg at a current dose of 100 μA (p =
0.019), but not on the forearm at either dose (p = 0.47).
In patients, the area of histamine ﬂare on the leg was inversely
correlated with the clinical status, as shown in ﬁgure 2. P01,
P03, and P04 were the most aﬀected patients, having con-
comitant small and large nerve ﬁber neuropathy and abnormal
sensory nerve action potentials. This correlation held up
whether values for the histamine ﬂare area were taken from
visit 1 (Spearman R2 0.73, p = 0.09) or visit 2 (R2 0.85, p =
0.03). Indeed, ﬂare areas on both visits were nearly identical in
4 of the 6 patients, although further apart in the other 2.
The intraindividual variation in the histamine ﬂare area from
visit 1 to visit 2 is shown more completely in ﬁgure 3 (which
for the sake of brevity only displays data obtained from the
Table 2 Results of QST in the control and patient groups
Controls Patients
p
ValueMedian IQR Median IQR
Hand
Detection,
warm
34.4 33.4–36.1 36.1 35.1–40.5 0.053
Detection,
cold
31.2 30.2–31.3 30.4 28.8–30.7 0.025
Pain, warm 44.9 42.9–47.7 43.5 40.1–48.2 ns
Pain, cold 14.2 7.5–20.2 8.6 3.2–10.5 ns
Foot
Detection,
warm
37.4 35.3–39.2 43.0 39.0–47.6 0.003
Detection,
cold
28.5 27.3–29.8 26.3 4.0–28.3 0.040
Pain, warm 45.7 44.6–46.6 48.6 46.5–50.0 ns
Pain, cold 7.7 2.7–21.9 2.1 0.0–8.8 ns
Abbreviations: IQR = interquartile range; QST = quantitative sensitivity
testing.
Measurements made on the left and right sides were considered as repli-
cates: averaged at the individual level and then summarized for the 2 groups
as indicated. All values are absolute temperature in °C.
p Values refer to the comparison of patients with controls.
Figure 1 Histamine flare in patients and controls
Measurements made on the left and right sides of the same person were considered replicates, averaged and plotted as shown, for each study participant.
The box plots indicate themedian, interquartile range, and extreme values. *p < 0.05 patients vs controls. **p < 0.01 iontophoretic dose of 100 vs 20 μA. The
red line corresponds to the positive control patient (table 1).
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highest iontophoretic current dose) in the form of Bland and
Altman plots. These plots reveal negligible bias (none of
which reached statistical signiﬁcance), but relatively wide
limits of agreement.
As evaluated from ROC curve analysis (ﬁgure 4), the ability of
histamine ﬂare to discriminate between patients and controls
was similar on visit 1 (AUC 0.81) and visit 2 (0.77). Fur-
thermore, the performances of histamine ﬂare and QST
testing were comparable (AUC for QST testing, 0.78).
Discussion
Based on our previous experience in quantifying spatial dis-
tribution of SkBF with LDI,12,15,16 we present here the
ﬁndings from a prospective study comparing LDIﬂare in
patients with FAP and controls. Our results indicate that axon
reﬂex-mediated neurogenic cutaneous vasodilation in re-
sponse to histamine measured by LDI (1) is easily elicited in
both groups of participants, (2) is only moderately re-
producible at the intraindividual level, (3) despite this latter
limitation appears clearly reduced in patients according to
a length-dependent pattern, and (4) shows an ability similar
to QST testing for discriminating between patients and
controls.
The reproducibility of our results was assessed by intra-
individual variation in the histamine ﬂare area from visit 1 to
visit 2 (ﬁgure 3), revealing negligible bias with no statistical
signiﬁcance, but relatively wide limits of agreement. This re-
sult is in accordance with what is already known in LDIﬂare
studies.17,18
We showed a length-dependent pattern in our patients with
FAP: the histamine ﬂare response on the leg was less intense
in patients than in controls, at least for the higher dose of
histamine, whereas it did not diﬀer, at either dose, between the
2 groups on the forearm. This result is consistent with QST
testing: in patients, the detection thresholds for cold and
warm were clearly more abnormal in the feet compared with
the hands (table 2). This is in line with observations reported
by others in patients with FAP despite the subjectivity of QST
testing.1
Among the tests for small ﬁber function,3 QST is considered
a gold standard tool.1,19 In terms of ability to discriminate
between patients and healthy controls, LDIﬂare has been
variously reported as inferior to QST in diabetic neuropa-
thies20 or equivalent in neuropathies of mixed etiologies.21 In
keeping with this latter study, ROC curve analysis in our case
showed a similar performance of histamine ﬂare and QST
(ﬁgure 4). The discrepancy between studies could reﬂect
methodological diﬀerences. Alternatively, it may be related to
Figure 2 Relationship between Neurologic Severity Score and the area of histamine flare on the leg
R2: Spearman rank correlation coefficient. Data points
labeled according to the patient ID (table 1). NIS-LL =
Neurological Impairment Score–Lower Limbs; PC =
positive control.
Figure 3Bland andAltmanplots of histamine flare areas on
the leg, recorded on visits 1 and 2
Data from flares induced with the 100 μA iontophoretic current on the leg.
Full horizontal lines: average difference across participants (bias). Dashed
lines: limits of agreement. Numerical values for bias and limits of agreement
shown on each plot, expressed in cm2.
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diﬀerent sample sizes and case mix. Our patients had pe-
ripheral neuropathies of homogeneous etiology. However,
their small number precludes any meaningful calculation of
cutoﬀ points for estimating the respective sensitivities and
speciﬁcities of LDIﬂare and QST. A larger study is required to
that eﬀect, keeping in mind that the ultimate clinical useful-
ness of these tests would depend on their negative/positive
predictive values. The latter, in addition to speciﬁcity and
sensitivity, are in turn determined by the prevalence of the
condition under investigation.
An important result of our study is the correlation between
the LDIﬂare area and NIS-LL, a score recently found to be
a valid and reliable measure of TTR-FAP severity.17 This
a new correlation being up to now only demonstrated by
nerve biomarkers obtained from skin biopsies.22 This is valid
for our patients independently of clinical small or large nerve
ﬁber involvement or absent/reduced sensory nerve action
potentials on nerve conduction studies.
The current study has limitations. Considering FAP hetero-
geneity,1 our small patient sample may not be representative.
However, our data provide a rationale for the use of reﬂex-
mediated neurogenic cutaneous vasodilatation in response to
histamine in a larger scale. This reﬂex measured by LDI is an
objective and quantitative measure that can potentially serve
as a useful biomarker, assessing TTR-FAP severity in
epidemiologic surveys and therapeutic trials, even at an early
disease stage.
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